BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was CHF 0.783 million compared to CHF 379.82 million a year ago. Net loss was CHF 532.93 million compared to net income of CHF 349.5 million a year ago. Basic loss per share from continuing operations was CHF 9.66 compared to basic earnings per share from continuing operations of CHF 6.31 a year ago. Diluted loss per share from continuing operations was CHF 9.66 compared to diluted earnings per share from continuing operations of CHF 6.31 a year ago.